GGrantIndex
← Leaderboards

Bing Xu

Brandeis University

$6,164,479
Attributed
$7,364,841
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $773K · FY201025
$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,364,841 · 5

By mechanism

R01$5,950,354 · 1
R21$1,251,987 · 3
R03$162,500 · 1

Top collaborators

Others in their field

Top investigators on “Self Assembly

Research focus

Self AssemblyEnzymesIn VivoCellsDesignMolecularCancer TherapyNanofiberSmall MoleculeLigandsMolecular Assembly/Self AssemblyInnovationCancer CellLeadPeptidesTumorMalignant NeoplasmsCell PhysiologyNanomedicineAntineoplastic AgentsMouse ModelFutureNovel StrategiesAnticancer Treatment

Grant awards (25)

Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$397,052
R01 · FY2025 · CA · contact PI
Selectively eliminating residual human induced pluripotent stem cells (iPSCs) in cell mixtures for cell therapy$181,265
R21 · FY2025 · EY · contact PI
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$579,612
R01 · FY2024 · CA · contact PI
Selectively eliminating residual human induced pluripotent stem cells (iPSCs) in cell mixtures for cell therapy$193,351
R21 · FY2024 · EY · contact PI
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$397,052
R01 · FY2023 · CA · contact PI
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$389,109
R01 · FY2022 · CA · contact PI
Incorporation of quantitative SRS imaging in sEISA for developing anticancer nanomedicines$228,691
R01 · FY2022 · CA · contact PI
Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models$81,250
R03 · FY2022 · CA · contact PI
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$73,705
R01 · FY2022 · CA · contact PI
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines$417,322
R01 · FY2021 · CA · contact PI
Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models$81,250
R03 · FY2021 · CA · contact PI
Subcellular Enzyme-instructed self-assembly for molecular anticancer nanomedicines$51,237
R01 · FY2021 · CA · contact PI
Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer$430,496
R21 · FY2020 · CA · contact PI
Enzyme-instructed self-assembly for molecular anticancer nanomedicines$357,100
R01 · FY2019 · CA · contact PI
Enzyme-instructed self-assembly for molecular anticancer nanomedicines$368,145
R01 · FY2018 · CA · contact PI
Enzyme-instructed nanoscale assemblies for killing multidrug resistant bacteria$243,750
R21 · FY2018 · AI · contact PI
Enzyme-instructed self-assembly for molecular anticancer nanomedicines$368,145
R01 · FY2017 · CA · contact PI
Enzyme-instructed nanoscale assemblies for killing multidrug resistant bacteria$203,125
R21 · FY2017 · AI · contact PI
Enzyme-instructed self-assembly for molecular anticancer nanomedicines$368,145
R01 · FY2016 · CA · contact PI
Enzyme-instructed self-assembly for molecular anticancer nanomedicines$383,751
R01 · FY2015 · CA · contact PI
Enzyme-instructed self-assembly for anticancer nanomedicine$308,474
R01 · FY2014 · CA · contact PI
Enzyme-instructed self-assembly for anticancer nanomedicine$298,934
R01 · FY2013 · CA · contact PI
Enzyme-instructed self-assembly for anticancer nanomedicine$318,015
R01 · FY2012 · CA · contact PI
Enzyme-instructed self-assembly for anticancer nanomedicine$318,015
R01 · FY2011 · CA · contact PI
Enzyme-instructed self-assembly for anticancer nanomedicine$327,850
R01 · FY2010 · CA · contact PI